Eli Lilly and Company $LLY is Steel Grove Capital Advisors LLC’s 8th Largest Position

Steel Grove Capital Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3,241.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,618 shares of the company’s stock after acquiring an additional 20,001 shares during the quarter. Eli Lilly and Company accounts for approximately 1.9% of Steel Grove Capital Advisors LLC’s investment portfolio, making the stock its 8th biggest position. Steel Grove Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $16,072,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. PNC Financial Services Group Inc. boosted its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC boosted its stake in shares of Eli Lilly and Company by 7,975.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after buying an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 1.1%

LLY opened at $799.85 on Wednesday. The firm has a market cap of $757.03 billion, a price-to-earnings ratio of 52.28, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business’s 50 day moving average is $759.77 and its two-hundred day moving average is $766.43. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. BMO Capital Markets raised their target price on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.